Bradanicline

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Bradanicline, also known by its development code TC-5619, is a drug that was being developed by Targacept. It acts as a partial agonist at the alpha-7 subtype of nicotinic acetylcholine receptors in the brain and was studied for potential cognitive enhancement. Researchers explored its use as a treatment for schizophrenia and attention deficit disorders (ADHD). The project involved a collaboration with AstraZeneca, which could license the compound if it progressed. Phase I trials were completed, and it was moving toward Phase II. In May 2011, AstraZeneca chose not to license Bradanicline. In September 2012, Targacept ended its development for ADHD in adults. By late 2013, Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia, as well as for ADHD.